Several studies have reported that, for unresectable HCC, PD-1/PD-L1 inhibitors with antiangiogenic-targeted agents achieve significant objective responses and disease control rates (Finn et al., 2020a; Finn et al., 2020b; Xu et al., 2021). The gene discussed is CD274; the disease is hepatocellular carcinoma.